All In Biotech

Drug Trial Radar · NCT04509700

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

112

Actual

Start

Aug 3, 2020

Primary completion

Nov 5, 2026

Study completion Nov 5, 2026

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Aug 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.

Conditions

  • B-Cell Malignancies

Interventions

  • ParsaclisibDrug

    Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.

  • parsaclisib + itacitinibDrug

    Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.

  • parsaclisib + ruxolitinibDrug

    Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.

  • parsaclisib + ibrutinibDrug

    Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Through study completion, an average of 5 years

Locations

105 sites in 17 countries. Site status is shown where the registry gives one.

  • Uab Comprehensive Cancer Center

    Birmingham, Alabama

  • University of Alabama At Birmingham

    Birmingham, Alabama

  • Mayo Clinic Rochester

    Phoenix, Arizona

  • University of Arizona Cancer Center-Out Pt.

    Tucson, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • California Cancer Associates For Research and Excellence

    Fresno, California

  • Innovative Clinical Research Institute

    Long Beach, California

  • Rocky Mountain Cancer Center

    Aurora, Colorado

  • Rush University Medical Center-Consultants in Hematology

    Chicago, Illinois

  • University of Kansas Hospital Authority

    Westwood, Kansas

  • Rcca Md, Llc

    Bethesda, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan Cancer Center

    Ann Arbor, Michigan

  • Hattiesburg Clinic Hematology

    Hattiesburg, Mississippi

  • Saint Luke'S Hospital of Kansas City

    Kansas City, Missouri

  • Hca Midwest Health-Research Medical Center

    Kansas City, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University Hospitals Case Medical Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Knight Cancer Institute At Oregon Health and Science University

    Portland, Oregon

  • Baylor Scott White Univeristy Medical Center

    Dallas, Texas

  • University of Washington-Seattle Cancer Care Alliance

    Seattle, Washington

  • Medical University of Vienna

    Vienna, Austria

  • Cliniques Universitaires Ucl Saint-Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Gent (Uz Gent)

    Ghent, Belgium

  • Az Groeninge

    Kortrijk, Belgium

  • Universitaire Ziekenhuis Leuven - Gasthuisberg

    Leuven, Belgium

  • University Hospital Hradec Kralove

    Hradec Králové, Czechia

  • Univerzita Karlova V Praze 1. Lekarska Fakulta

    Prague, Czechia

  • Fakultni Nemocnice V Motole

    Prague, Czechia

  • University Hospital Kralovkse Vinohrady

    Prague, Czechia

  • Aarhus University Hospital

    Århus N, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Sjaellands Universitetshospital

    Roskilde, Denmark

  • Chru de Brest Hospital Morvan

    Brest, France

  • Centre Antoine Laccassagne

    Nice, France

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.